
|Articles|October 15, 2003
New drug developed to treat Fabry's disease
New York-Treatment is now available for Fabry's disease, a lysosomal storage disorder with ophthalmologic findings. In April, the FDA granted Orphan Drug designation for agalsidase beta (Fabrazyme, Genzyme General), an enzyme replacement therapy, for the treatment of this progressive and potentially fatal disease.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Rayner announces Sophi Phaco System in the US
2
Ophthalmology pipeline watch: Key trial results and PDUFA dates for Q1 2026
3
PRIMA retinal implant restores vision in patients with advanced GA
4
Q&A: Understanding Medicare payment shifts in eye care
5














































